In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible Escherichia coli and Klebsiella pneumoniae-Reference-Cited by-同舟云学术

In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible Escherichia coli and Klebsiella pneumoniae

Published:2010-06 Issue:6 Volume:35 Page:609-610
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Netikul Thidarat,Leelaporn Amornrut,Leelarasmee Amorn,Kiratisin Pattarachai

Funder

Siriraj Research Development Fund

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference7 articles.

1. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia;Borer;Infect Control Hosp Epidemiol,2009

2. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin;Falagas;Int J Antimicrob Agents,2010

3. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections;Roussos;Int J Antimicrob Agents,2009

4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.

5. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel;Navon-Venezia;Antimicrob Agents Chemother,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies;Antibiotics;2020-08-10

2. Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: Review and mapping of emerging and overlapping challenges;International Journal of Antimicrobial Agents;2019-10

3. Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocci;Enfermedades Infecciosas y Microbiología Clínica;2019-01

4. Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocci;Enfermedades infecciosas y microbiologia clinica (English ed.);2019-01

5. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology;Enfermedades Infecciosas y Microbiología Clínica;2015-05